Interestingly, all 8 patients with breast cancer responding to MET were hormone receptor–positive (HR+), and HR+ status was significantly associated with anti-MET response (P = 0.0448, Figure 1, C and D). The gene discussed is NR4A1; the disease is breast cancer.